There are currently 1140 clinical trials in Cincinnati, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Cincinnati Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)
NCT04965636
Recruiting
The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of care (SoC) therapy.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
08/08/2023
Locations: GSK Investigational Site, Cincinnati, Ohio
Conditions: Hypereosinophilic Syndrome
Register for Updates
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
NCT05973799
Recruiting
Iatrogenic hypoglycemia is still considered to be the number one barrier to effective glycemic control in patients with type 1 diabetes (T1D). In a previous study, it was observed in people without diabetes that fasting can be detrimental to the hormonal and hepatic responses to insulin-induced hypoglycemia. In the experiments described herein, the impact fasting has on hypoglycemic counterregulation in people with T1D will be determined.
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
08/02/2023
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Hypoglycemia, type1diabetes
Register for Updates
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
NCT05985161
Recruiting
The purpose of this study is to find out whether selinexor is an effective treatment for people under the age of 51 who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.
Gender:
All
Ages:
12 months and above
Trial Updated:
08/02/2023
Locations: Cincinnati Children's Hospital Medical Center (Data collection only), Cincinnati, Ohio
Conditions: Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST, Nephroblastoma, XPO1 Gene Mutation, Solid Tumor
Register for Updates
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
NCT05225584
Recruiting
This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Adult patients with Relapsed or Refractory (R/R) Lymphomas, Large Granular Lymphocytic Leukemia (LGL-L), T-cell prolymphocytic leukemia (T-PLL), and Solid Tumors. The Phase 1a stage of the study will explore escalating doses of single-agent KT-333. The Phase Ib stage will consist of 4 expansion cohorts to further characterize the safety, tolerability and the pharmacokineti... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2023
Locations: The Christ Hospital Cancer Center, Cincinnati, Ohio
Conditions: Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), Solid Tumors, T-cell Prolymphocytic Leukemia (T-PLL)
Register for Updates
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
NCT03767348
Recruiting
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/01/2023
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
Register for Updates
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
NCT03186898
Recruiting
This phase III trial studies how well radiation therapy with protons works compared with photons in treating patients with liver cancer. Radiation therapy, such as photon therapy, uses high energy x-rays to send the radiation inside the body to the tumor while proton therapy uses a beam of proton particles. Proton therapy can stop shortly after penetrating through the tumor and may cause less damage to the surrounding healthy organs and result in better survival in patients with liver cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/31/2023
Locations: University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio
Conditions: Unrectable or Locally Recurrent Hepatocellular Carcinoma
Register for Updates
Evaluating Additive Effects of Including Canines in Regulating Together
NCT05803343
Recruiting
The primary objective is to evaluate the potential additive effect of animal-assisted intervention (AAI) on a manualized behavioral treatment targeting emotion dysregulation (ED) in children with autism spectrum disorder (ASD). Aim 1: Evaluate whether Regulating Together-Canine demonstrates earlier and greater improvement in emotion dysregulation than Regulating Together-Standard. Aim 2: Evaluate if Regulating Together-Canine increases child engagement and learning compared to Regulating Toget... Read More
Gender:
All
Ages:
Between 8 years and 15 years
Trial Updated:
07/27/2023
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Autism Spectrum Disorder, Emotion Regulation
Register for Updates
Therapeutic Response Evaluation and Adherence Trial (TREAT)
NCT02286154
Recruiting
The primary objectives of this prospective study of hydroxyurea for children with sickle cell anemia are 1) Develop and prospectively evaluate a population pharmacokinetic/pharmacodynamics model to predict the maximum tolerated dose (MTD); 2) Identify urine biomarkers of hydroxyurea adherence using a novel metabolomics approach; 3) Identify pharmacogenomics modifiers of hydroxyurea MTD; and 4) Longitudinal monitoring of the effect of hydroxyurea upon organ function and quality of life.
Gender:
All
Ages:
Between 6 months and 21 years
Trial Updated:
07/27/2023
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Anemia, Sickle Cell
Register for Updates
Trial of Parkinson's And Zoledronic Acid
NCT03924414
Recruiting
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the Nationa... Read More
Gender:
All
Ages:
60 years and above
Trial Updated:
07/24/2023
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism, Atypical Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Vascular Parkinsonism, Dementia With Lewy Bodies
Register for Updates
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
NCT05219110
Recruiting
The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E. coli (STEC) infection in children and adolescents when compared with traditional approaches (conservative fluid management).
Gender:
All
Ages:
Between 9 months and 21 years
Trial Updated:
07/21/2023
Locations: Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Register for Updates
Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG
NCT05957549
Recruiting
Individuals with Fragile X Syndrome show differences in how they understand and learn language from infancy. They frequently have lifelong delays in speech and language as well. In addition, they experience other auditory symptoms, including being very sensitive to certain sounds as well as being more sensitive than others to loud sounds. The underlying brain activity for sound perception and speech learning in Fragile X is not well understood, especially in the infant and toddler years. This st... Read More
Gender:
All
Ages:
Between 6 months and 5 years
Trial Updated:
07/20/2023
Locations: Cincinnati Children'S Hospital, Cincinnati, Ohio
Conditions: Fragile X Syndrome
Register for Updates
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
NCT04372615
Recruiting
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/19/2023
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Autoimmune Encephalitis, Encephalitis
Register for Updates